Search results
Results from the WOW.Com Content Network
The drug, fluvoxamine, ... The drug also cut the odds of COVID-related death. Of the participants, 12 who were given a placebo died, while just one taking fluvoxamine did.
The drug was studied because of its anti-inflammatory effects, but the mechanism of action against COVID-19 remains uncertain. [38] [39] [40] On 16 December, the NIH found that use of fluvoxamine did not impact incidence of covid-related hospitalizations and considered the evidence insufficient to recommend either for or against the drug. [41]
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [8] It is primarily used to treat major depressive disorder and, perhaps more-especially, obsessive–compulsive disorder (OCD), [9] but is also used to treat anxiety disorders [10] such as panic disorder, social anxiety disorder, and post-traumatic stress ...
The rate of long COVID was 42% lower among participants who took the medication, trial data show. Could a common diabetes drug help prevent long COVID? Trial shows promising results
[52] [53] [54] As of July 2021, a large number of drugs had been considered for treating COVID-19 patients. [55] As of November 2022, there was moderate-certainty evidence suggesting that dexamethasone, and systemic corticosteroids in general, probably cause a slight reduction in all-cause mortality (up to 30 days) in hospitalized patients with ...
Jan. 19—Kern Medical announced Tuesday that the facility will administer doses of a newly-approved medication that shields vulnerable populations from a deadly infection of COVID-19.
In March 2020, then US President Donald Trump promoted the use of chloroquine and hydroxychloroquine, two related anti-malarial drugs, for treating COVID-19. The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19.
Peter Roger Breggin (born May 11, 1936) [1] is an American psychiatrist and critic of shock treatment and psychiatric medication and COVID-19 response. In his books, he advocates replacing psychiatry's use of drugs and electroconvulsive therapy with psychotherapy, education, empathy, love, and broader human services.